Leheny A. Rachel 4

What Happened Leheny A. Rachel, Chief Executive Officer of CalciMedica, was granted an equity award of 148,482 shares (reported as a derivative acquisition, code A) at a $0.00 price. The grant is reported in the Form 4 covering the period ended 2026-04-05 (accession 2026-04-07); the transaction date listed in the filing is 2025-04-05. No cash was paid for the award — it is a compensation grant rather than a market purchase.

Key Details

• Transaction date (as reported): 2025-04-05; Form 4 filed/accessioned: 2026-04-07 (period of report 2026-04-05).
• Amount: 148,482 shares; Price: $0.00 per share (derivative award, code A).
• Shares owned after transaction: not stated in the provided filing details.
• Footnote (vesting): Beginning April 1, 2026, 1/48th of the shares subject to the option vest monthly over four years — however, no shares will vest until the company files a registration statement on Form S-8 covering the shares added under the plan via the annual “evergreen” provision.
• Timeliness: the filing shows the Form 4 accession on 2026-04-07; the filing does not include a timeliness code in the summary provided here.

Context This was an equity award (compensation grant), not a stock purchase or sale. Because the award is a derivative subject to a multi-year vesting schedule and conditioned on a Form S-8 registration, the shares are not immediately tradable. Awards like this are common executive compensation and do not, by themselves, indicate an immediate bullish or bearish signal.